Mandate

Vinge advises Isofol in connection with IPO

March 14, 2017

Vinge has advised Isofol Medical AB (publ) in connection with its listing on Nasdaq First North Premier. As a part of the offer, a new issue of shares directed to the general public and institutional investors has been conducted which is expected to generate MSEK 430-473 for Isofol depending on whether an over-subscription option is exercised.

The prospectus is expected to be published on 20 March 2017 and the first day of trading on First North Premier is planned for 4 April 2017. The subscription price in the offer is SEK 29 per share, which corresponds to a value of Isofol of approximately MSEK 487 prior to the offer.

Isofol is an oncology company which clinically develops Modufolin which is a first choice medicament in conjunction with treatment of spread colorectal cancer and is standard therapy in conjunction with high dosage treatment with metotrexat of osteosarcoma. Isofol thus intends to replace the existing folate-based medicaments leukovorin and levoleukovorin, which are currently considered to be the standard treatment within these treatment areas.

Through a worldwide, exclusive license agreement Isofol Medical holds all rights to a global commercialization of Modufolin for cancer treatment as well as access to Merck KGaA’s (Darmstadt, Germany) patent-protected manufacturing process and production capacity.

Vinge’s team primarily consisted of responsible partner Anders Strid, partners Jesper Schönbeck and Magnus Pauli, associates Frida Bäckegren, Natalie Bäck, Petronella Hallberg, Victor Ericsson and company assistant Camilla Andersson.

Related

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025